OncoMed Pharma (OMED) Tops Q4 EPS by 8c

OncoMed Pharma (NASDAQ: OMED) reported Q4 EPS of ($0.60), $0.08 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $8.89 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Nike (NKE) Tops Q1 EPS by 4c
• Barclays Upgrades Universal Music Group NV (UMG:NA) (UMGNF) to Overweight
• ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance